Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > September 16, 2022
Daily News
September 16, 2022
- Moderna in Talks with Govt on Building Vaccine Plant in Japan: CEO
September 16, 2022
- Asahi Kasei Bags Japan Commercial Rights for Two Sobi Treatments
September 16, 2022
- Shionogi’s COVID Pill Might Not Be Applicable for Emergency Approval: JPMA Exec
September 16, 2022
- JPMA Managing Director Tanaka to Retire, Ex-Chugai Official to Take Over
September 16, 2022
- JPMA to Present Proposal on Value-Based Drug Pricing at Upcoming Panel Hearing
September 16, 2022
- Kyowa Kirin Seeks Palmoplantar Pustulosis Nod for Lumicef in Japan
September 16, 2022
- Insmed CEO Sees Japan as Cornerstone of APAC Strategy, Doubling of Staff in Next 2 Years
September 16, 2022
- Govt’s Economic Security Panel Discusses Plan for Supply Chain Survey
September 16, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…